|Last Price||Today's Change||52-Week Range||Trading Volume|
|96.61||1.06 (+1.11%)||82.51 - 154.89||663.4 thousand (Below Avg)|
Market data as of 4:00PM 07/22/14. Quotes are delayed by at least 15 min.
IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study
05/31/2014 8:05 AM ET